Cargando…

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

IMPORTANCE: Despite approximately 40% of patients having Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of at least 2 in the real world, most landmark clinical trials that led to the use of pembrolizumab as standard of care in advanced non–small cell lung cancer (NSCLC) exc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sehgal, Kartik, Gill, Ritu R., Widick, Page, Bindal, Poorva, McDonald, Danielle C., Shea, Meghan, Rangachari, Deepa, Costa, Daniel B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879233/ https://www.ncbi.nlm.nih.gov/pubmed/33570575 http://dx.doi.org/10.1001/jamanetworkopen.2020.37120

Ejemplares similares

In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer
por: Bindal, Poorva, et al.
Publicado: (2020)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
por: Sehgal, Kartik, et al.
Publicado: (2021)

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Takahashi, Masato, et al.
Publicado: (2023)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
por: Popat, Sanjay, et al.
Publicado: (2022)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
por: Mathew Thomas, Vinay, et al.
Publicado: (2019)

Chordoma: A Case Report and Review of Literature
por: Noor, Arish, et al.
Publicado: (2020)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Orphan nuclear receptor ftz-f1 (NR5A3) promotes egg chamber survival in the Drosophila ovary
por: Beachum, Allison N, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

The Right Hemisphere in Esthetic Perception
por: Bromberger, Bianca, et al.
Publicado: (2011)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children
por: Villacis-Nunez, D. Sofia, et al.
Publicado: (2022)

Primary Bone Lymphoma: A Case Series and Review of Literature
por: Bindal, Poorva, et al.
Publicado: (2020)

Idiopathic Granulomatous Mastitis-A Mystery Yet to be Unraveled: A Case Series and Review of Literature
por: Mathew Thomas, Vinay, et al.
Publicado: (2020)

Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
por: Galán, Rocío Jiménez, et al.
Publicado: (2021)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
por: Eggermont, Alexander M. M., et al.
Publicado: (2020)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
por: Ngoi, N.Y.L., et al.
Publicado: (2018)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi, Susumu, et al.
Publicado: (2020)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f4np35tojq8cgktsk6d9s37csp